Journal
BRITISH JOURNAL OF CANCER
Volume 103, Issue 3, Pages 291-296Publisher
SPRINGERNATURE
DOI: 10.1038/sj.bjc.6605768
Keywords
aromatase inhibitor; arthralgia; breast cancer; cytokine
Categories
Funding
- Pfizer
- AstraZeneca
- Lilly
- Novartis
Ask authors/readers for more resources
BACKGROUND: The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers. METHODS: Patients with breast cancer were enroled in a trial of adjuvant AI therapy. Changes in pain and function during therapy were assessed prospectively. We selected 30 cases with AIMSS and 22 controls without AIMSS, matched for demographics and prior therapy. Serum samples collected at baseline and during treatment were assayed for multiple inflammatory cytokines and lipid mediators using multiplex assays. RESULTS: Before AI therapy, mean serum concentrations of 6 of 36 assayed factors were statistically significantly lower in cases than controls (all P<0.003). No statistically significant changes during AI therapy relative to pre-treatment were observed between cases and controls for any of the inflammatory markers tested. CONCLUSION: AIMSS is probably not associated with a systemic inflammatory response. Pre-treatment cytokine levels may predict for development of AIMSS. British Journal of Cancer (2010) 103, 291-296. doi:10.1038/sj.bjc.6605768 www.bjcancer.com Published online 6 July 2010 (C) 2010 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available